Center Laboratories (4123) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Center Laboratories (4123) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$46.61 Million ≈ $1.47 Million USD) by net assets (NT$19.64 Billion ≈ $618.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Center Laboratories - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Center Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Center Laboratories balance sheet liabilities for a breakdown of total debt and financial obligations.
Center Laboratories Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Center Laboratories ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
0.031x |
|
Guangdong Fuxin Technology Co. Ltd. A
SHG:688662
|
0.072x |
|
Beijing Philisense Tech
SHE:300287
|
-0.021x |
|
Koza Anadolu Metal Madencilik Isletmeleri AS
IS:KOZAA
|
0.122x |
|
SolGold Plc
F:S8F
|
0.128x |
|
Metalurgica Gerdau S.A
SA:GOAU3
|
0.053x |
|
Sipef NV
BR:SIP
|
0.138x |
|
Aeva Technologies, Inc. Common Stock
NYSE:AEVA
|
-0.447x |
Annual Cash Flow Conversion Efficiency for Center Laboratories (2006–2024)
The table below shows the annual cash flow conversion efficiency of Center Laboratories from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see 4123 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$18.05 Billion ≈ $568.82 Million |
NT$415.71 Million ≈ $13.10 Million |
0.023x | +148.32% |
| 2023-12-31 | NT$20.22 Billion ≈ $636.92 Million |
NT$-963.44 Million ≈ $-30.35 Million |
-0.048x | -383.21% |
| 2022-12-31 | NT$19.25 Billion ≈ $606.55 Million |
NT$-189.88 Million ≈ $-5.98 Million |
-0.010x | +41.91% |
| 2021-12-31 | NT$21.09 Billion ≈ $664.61 Million |
NT$-358.14 Million ≈ $-11.28 Million |
-0.017x | -29.96% |
| 2020-12-31 | NT$20.63 Billion ≈ $650.10 Million |
NT$-269.56 Million ≈ $-8.49 Million |
-0.013x | +29.50% |
| 2019-12-31 | NT$15.46 Billion ≈ $487.02 Million |
NT$-286.45 Million ≈ $-9.02 Million |
-0.019x | -146.39% |
| 2018-12-31 | NT$15.47 Billion ≈ $487.30 Million |
NT$617.84 Million ≈ $19.47 Million |
0.040x | -66.54% |
| 2017-12-31 | NT$16.87 Billion ≈ $531.48 Million |
NT$2.01 Billion ≈ $63.44 Million |
0.119x | +63.44% |
| 2016-12-31 | NT$15.82 Billion ≈ $498.51 Million |
NT$1.16 Billion ≈ $36.41 Million |
0.073x | +886.07% |
| 2015-12-31 | NT$14.88 Billion ≈ $468.92 Million |
NT$-138.29 Million ≈ $-4.36 Million |
-0.009x | -754.87% |
| 2014-12-31 | NT$6.94 Billion ≈ $218.54 Million |
NT$-7.54 Million ≈ $-237.52K |
-0.001x | -113.13% |
| 2013-12-31 | NT$5.01 Billion ≈ $157.93 Million |
NT$41.50 Million ≈ $1.31 Million |
0.008x | +77.01% |
| 2012-12-31 | NT$3.47 Billion ≈ $109.32 Million |
NT$16.23 Million ≈ $511.33K |
0.005x | -85.23% |
| 2011-12-31 | NT$2.21 Billion ≈ $69.75 Million |
NT$70.11 Million ≈ $2.21 Million |
0.032x | +1890.25% |
| 2010-12-31 | NT$2.18 Billion ≈ $68.76 Million |
NT$-3.86 Million ≈ $-121.64K |
-0.002x | -109.56% |
| 2009-12-31 | NT$2.11 Billion ≈ $66.57 Million |
NT$39.11 Million ≈ $1.23 Million |
0.019x | -76.35% |
| 2008-12-31 | NT$573.09 Million ≈ $18.06 Million |
NT$44.86 Million ≈ $1.41 Million |
0.078x | -45.54% |
| 2007-12-31 | NT$471.17 Million ≈ $14.84 Million |
NT$67.71 Million ≈ $2.13 Million |
0.144x | +1.12% |
| 2006-12-31 | NT$273.07 Million ≈ $8.60 Million |
NT$38.81 Million ≈ $1.22 Million |
0.142x | -- |
About Center Laboratories
Center Laboratories, Inc., a pharmaceutical company, develops, manufactures, and sells pharmaceuticals in Taiwan and internationally. The company offers general medication pharmaceuticals comprising antipyretics and analgesics, bronchodilators, anti-inflammatory preparations, antihistamines, expectorants, narcotic antitussives and expectorants, gastrointestinal preparations, non-narcotic antituss… Read more